Publicaciones en colaboración con investigadores/as de Duke University (16)

2024

  1. Ticagrelor with or without aspirin following percutaneous coronary intervention in high-risk patients with concomitant peripheral artery disease: A subgroup analysis of the TWILIGHT randomized clinical trial

    American Heart Journal, Vol. 272, pp. 11-22

2023

  1. Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions

    Journal of the American College of Cardiology, Vol. 82, Núm. 8, pp. 687-700

  2. Differential predictability for high-risk plaque characteristics between fractional flow reserve and instantaneous wave-free ratio

    Scientific Reports, Vol. 13, Núm. 1

  3. Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention

    JACC: Cardiovascular Interventions, Vol. 16, Núm. 20, pp. 2514-2524

2022

  1. Prognostic Impact of Coronary Flow Reserve in Patients With Reduced Left Ventricular Ejection Fraction

    Journal of the American Heart Association, Vol. 11, Núm. 15, pp. e025841

  2. Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study

    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Vol. 17, Núm. 16, pp. 1330-1339

  3. Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study

    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Vol. 18, Núm. 11, pp. e897-e909

2021

  1. Instantaneous wave-free ratio guided multivessel revascularisation during percutaneous coronary intervention for acute myocardial infarction: Study protocol of the randomised controlled iMODERN trial

    BMJ Open, Vol. 11, Núm. 1

  2. Sex Differences among Patients with High Risk Receiving Ticagrelor with or without Aspirin after Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial

    JAMA Cardiology, Vol. 6, Núm. 9, pp. 1032-1041

2020

  1. Ticagrelor alone vs.Ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS

    European Heart Journal, Vol. 41, Núm. 37, pp. 3533-3545

2019

  1. Clinical Events After Deferral of LAD Revascularization Following Physiological Coronary Assessment

    Journal of the American College of Cardiology, Vol. 73, Núm. 4, pp. 444-453

  2. Comparison of Major Adverse Cardiac Events between Instantaneous Wave-Free Ratio and Fractional Flow Reserve-Guided Strategy in Patients with or Without Type 2 Diabetes: A Secondary Analysis of a Randomized Clinical Trial

    JAMA Cardiology, Vol. 4, Núm. 9, pp. 857-864

  3. Sex Differences in Instantaneous Wave-Free Ratio or Fractional Flow Reserve–Guided Revascularization Strategy

    JACC: Cardiovascular Interventions, Vol. 12, Núm. 20, pp. 2035-2046

  4. Ticagrelor with or without aspirin in high-risk patients after PCI

    New England Journal of Medicine, Vol. 381, Núm. 21, pp. 2032-2042

2018

  1. Safety of the Deferral of Coronary Revascularization on the Basis of Instantaneous Wave-Free Ratio and Fractional Flow Reserve Measurements in Stable Coronary Artery Disease and Acute Coronary Syndromes

    JACC: Cardiovascular Interventions, Vol. 11, Núm. 15, pp. 1437-1449

2017

  1. Use of the instantaneous wave-free ratio or fractional flow reserve in PCI

    New England Journal of Medicine, Vol. 376, Núm. 19, pp. 1824-1834